Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

New England Journal of Medicine

Volumn 361, Issue 23, 2009, Pages 2209-2220

  Rerks Ngarm, Supachai ^a   Pitisuttithum, Punnee ^b   Nitayaphan, Sorachai ^c   Kaewkungwal, Jaranit ^b   Chiu, Joseph ^c   Paris, Robert ^a,c   Premsri, Nakorn ^k   Namwat, Chawetsan ^a   De Souza, Mark ^c   Adams, Elizabeth ^d   Benenson, Michael ^c   Gurunathan, Sanjay ^e   Tartaglia, Jim ^e   McNeil, John G ^e   Francis, Donald P ^f   Stablein, Donald ^g   Birx, Deborah L ^h   Chunsuttiwat, Supamit ^a   Khamboonruang, Chirasak ^a   Thongcharoen, Prasert ^a   Robb, Merlin L ⁱ   Michael, Nelson L ⁱ   Kunasol, Prayura ^a   Kim, Jerome H ^i,j   more..

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e SANOFI PASTEUR   (France)

^f Global Solutions for Infectious Diseases   (United States)

^g EMMES CORPORATION   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^j US Army Medical Materiel Development Activity   (United States)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC HIV; CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VACCINE; VCP 1521; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ARTICLE; BLINDNESS; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THAILAND; UNSPECIFIED SIDE EFFECT; VACCINATION; VIREMIA; VIRUS LOAD; BLOOD; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; KAPLAN MEIER METHOD; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; THAILAND; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 73349094086     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0908492     Document Type: Article

References (46)

1. Brown T, Peerapatanapokin W. The Asian epidemic model: a process model for exploring HIV policy and programme alternatives in Asia. Sex Transm Infect 2004;80:Suppl 1:i19-i24.
2. Phoolcharoen W. HIV/AIDS prevention in Thailand: success and challenges. Science 1998;280:1873-4.
3. Weniger BG, Limpakarnjanarat K, Ungchusak K, et al. The epidemiology of HIV infection and AIDS in Thailand. AIDS 1991;5 Suppl 2:S71-S85. [Erratum, AIDS 1993;7:following 147.]
4. Nelson KE, Celentano DD, Eiumtrakol S, et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. N Engl J Med 1996;335:297-303.
5. Nitayaphan S, Brown AE. Preventive HIV vaccine development in Thailand. AIDS 1998;Suppl:S155-S161.
6. Hanenberg RS, Rojanapithayakorn W, Kunasol P, Sokal DC. Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases. Lancet 1994;344:243-5.
7. Nelson KE, Celentano DD, Suprasert S, et al. Risk factors for HIV infection among young adult men in northern Thailand. JAMA 1993;270:955-60.
8. Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. HIV/AIDS preventive vaccine 'primeboost' phase III trial: foundations and initial lessons learned from Thailand. AIDS 2006;20:1471-9.
9. National AIDS Prevention and Alleviation Committee. UNGASS country progress report: Thailand. Reporting Period January 2006 - December 2007. (Accessed October 19, 2009, at http://data.unaids.org/pub/Report/2008/thailand- 2008-country-progress-report-en.pdf.)
10. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998;12:2407-15.
11. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-80.
12. Russell ND, Graham BS, Keefer MC, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007;44:203-12.
13. The AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with rgp120. J Infect Dis 2001;183:563-70.
14. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-8.
15. Verrier F, Burda S, Belshe R, et al. A human immunodeficiency virus primeboost immunization regimen in humans induces antibodies that show intercalde cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J Virol 2000;74:10025-33.
16. Zolla-Pazner S, Xu S, Burda S, Duliege AM, Excler JL, Clements-Mann ML. Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines. J Infect Dis 1998;178:1502-6.
17. Nitayaphan S, Pitisuttithum P, Karnasuta C, et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004;190:702-6.
18. Thongcharoen P, Suriyanon V, Paris RM, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007;46:48-55.
19. Nitayaphan S, Khamboonruang C, Sirisophana N, et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 2000;18:1448-55.
20. Pitisuttithum P, Berman PW, Phonrat B, et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 2004;37:1160-5. [Erratum, J Acquir Immune Defic Syndr 2004;37:1669.]
21. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194:1661-71.
22. Pitisuttithum P, Nitayaphan S, Thongcharoen P, et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis 2003;188:219-27.
23. Kibuuka H, Kimutai R, Maboko L, et al. A phase I/II study of a multiclade HIV-1 DNA plasmid prime and recombinant Adenovirus-type 5 boost vaccine in HIV uninfected East Africans. J Infect Dis (in press).
24. Currier JR, Kuta EG, Turk E, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157-72.
25. Fu TM, Dubey SA, Mehrotra DV, et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 2007;23:67-76.
26. Gilbert PB, Bosch RJ, Hudgens MG. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics 2003;59:531-41.
27. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001;183:1343-52.
28. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:1230-46.
29. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002;29:254-61.
30. Lee D, Graham BS, Chiu YL, et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 2004;190:903-7.
31. Van Rompay KK, Abel K, Lawson JR, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005;38:124-34.
32. Pal R, Venzon D, Letvin NL, et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002;76:292-302.
33. Pal R, Venzon D, Santra S, et al. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006;80:3732-42.
34. Gilbert PB, Ackers ML, Berman PW, et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005;192:974-83.
35. Gilbert PB, Peterson ML, Follmann D, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005;191:666-77.
36. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-65.
37. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93.
38. Mascola JR, D'Souza P, Gilbert P, et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005;79:10103-7.
39. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccineinduced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007;178:6596-603.
40. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008;372:1894-905.
41. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008;8:247-58. [Erratum, Nat Rev Immunol 2008;8:486.]
42. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009;206:1273-89.
43. Karnasuta C, Paris RM, Cox JH, et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005;23:2522-9.
44. Ratto-Kim S, Loomis-Price LD, Aronson N, et al. Comparison between envspecific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults. J Acquir Immune Defic Syndr 2003;32:9-17.
45. Alter G, Teigen N, Ahern R, et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007;195:1452-60.
46. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009;206:1253-72.